SV

Street Verdict

Analyst Scorecard

A record of what Sumeet Bagadia said publicly, with the source. Not advice.

“Recommends buying Aarti Pharmalabs at ₹774.3 with a target of ₹830 and a stop loss at ₹725, citing a technical breakout.”

Sumeet Bagadia’s track record (trackable calls only): 1528 graded calls · 95% CI 32–37%

Aarti Pharmalabs LtdBullishCalled 19 Mar 2025Graded 25 Mar 2025
Verdict:MISS

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open.

Entry: ₹774.3, as stated.

Target ₹830, stop ₹725, as stated.

No time frame is stated, so it is tracked until a close reaches ₹830 or ₹725: there is no fixed window.

The stop ₹725 was reached on a close before the target ₹830. Miss.

The grader’s working: R3 TRADE_SETUP: entered ₹774.3 on 2025-03-20 (stated entry ₹774.3, LEVEL_CMP entry, filled); stop ₹725 breached at close ₹724 on 2025-03-25. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open.

Tracking Aarti Pharmalabs Ltd since this call

1-year tracking window
Read the original articleSee Sumeet Bagadia’s full track record